ondansetron has been researched along with Vestibular Neuronitis in 3 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Vestibular Neuronitis: Idiopathic inflammation of the VESTIBULAR NERVE, characterized clinically by the acute or subacute onset of VERTIGO; NAUSEA; and imbalance. The COCHLEAR NERVE is typically spared and HEARING LOSS and TINNITUS do not usually occur. Symptoms usually resolve over a period of days to weeks. (Adams et al., Principles of Neurology, 6th ed, p304)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ondansetron is an antiemetic 5-HT3 receptor antagonist with proven efficacy in central balance disorder." | 2.77 | A protective effect of 5-HT3 antagonist against vestibular deficit? Metoclopramide versus ondansetron at the early stage of vestibular neuritis: a pilot study. ( Biboulet, R; Mondain, M; Uziel, A; Venail, F, 2012) |
| "Vestibular neuritis is a neuroinflammatory, peripheral vestibular pathology leading to chronic deficits and long-term disability." | 1.39 | Ondansetron reduces lasting vestibular deficits in a model of severe peripheral excitotoxic injury. ( Broussy, A; Brugeaud, A; Chabbert, C; Dyhrfjeld-Johnsen, J; Gaboyard-Niay, S; Saleur, A, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Micarelli, A | 1 |
| Viziano, A | 1 |
| Panella, M | 1 |
| Micarelli, E | 1 |
| Alessandrini, M | 1 |
| Dyhrfjeld-Johnsen, J | 1 |
| Gaboyard-Niay, S | 1 |
| Broussy, A | 1 |
| Saleur, A | 1 |
| Brugeaud, A | 1 |
| Chabbert, C | 1 |
| Venail, F | 1 |
| Biboulet, R | 1 |
| Mondain, M | 1 |
| Uziel, A | 1 |
1 trial available for ondansetron and Vestibular Neuronitis
| Article | Year |
|---|---|
A protective effect of 5-HT3 antagonist against vestibular deficit? Metoclopramide versus ondansetron at the early stage of vestibular neuritis: a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Humans; Metoclopramide; Middle Aged; Ondansetron; Pilot | 2012 |
2 other studies available for ondansetron and Vestibular Neuronitis
| Article | Year |
|---|---|
Power spectra prognostic aspects of impulsive eye movement traces in superior vestibular neuritis.
Topics: Adult; Case-Control Studies; Eye Movement Measurements; Eye Movements; Female; Head Impulse Test; Hu | 2019 |
Ondansetron reduces lasting vestibular deficits in a model of severe peripheral excitotoxic injury.
Topics: Animals; Female; Kainic Acid; Models, Animal; Ondansetron; Rats; Vestibular Neuronitis | 2013 |